drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB08873 | DB11703 | 74 | 405 | [
"DDInter221",
"DDInter9"
] | Boceprevir | Acalabrutinib | Boceprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in... | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor... | Major | 2 | [
[
[
74,
25,
405
]
],
[
[
74,
63,
1101
],
[
1101,
24,
405
]
],
[
[
74,
25,
951
],
[
951,
24,
405
]
],
[
[
74,
25,
982
],
[
982,
63,
... | [
[
[
"Boceprevir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Boceprevir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarot... | Boceprevir may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Boceprevir may lead to a major life threatening interaction when taken with Palbociclib and Palbociclib may c... |
DB00980 | DB01069 | 969 | 401 | [
"DDInter1564",
"DDInter1533"
] | Ramelteon | Promethazine | Ramelteon is the first in a new class of sleep agents that selectively binds to the melatonin receptors in the suprachiasmatic nucleus (SCN). It is used for insomnia, particularly delayed sleep onset. Ramelteon has not been shown to produce dependence and has shown no potential for abuse. | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Moderate | 1 | [
[
[
969,
24,
401
]
],
[
[
969,
24,
1264
],
[
1264,
63,
401
]
],
[
[
969,
63,
104
],
[
104,
24,
401
]
],
[
[
969,
21,
28778
],
[
28778,
... | [
[
[
"Ramelteon",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Ramelteon",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
... | Ramelteon may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Ramelteon may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazi... |
DB00781 | DB01357 | 1,481 | 890 | [
"DDInter1489",
"DDInter1160"
] | Polymyxin B | Mestranol | Polymyxin B was discovered in the 1940s. They are basic polypeptides of about eight amino acids and have cationic detergent action on cell membranes. Polymyxin B is used for infections with gram-negative organisms, but may be neurotoxic and nephrotoxic[A176426,FDA Label]. All gram-positive bacteria, fungi, and the gram... | The 3-methyl ether of ethinyl estradiol. It must be demethylated to be biologically active. It is used as the estrogen component of many combination ORAL contraceptives. | Moderate | 1 | [
[
[
1481,
24,
890
]
],
[
[
1481,
24,
1438
],
[
1438,
1,
890
]
],
[
[
1481,
24,
50
],
[
50,
24,
890
]
],
[
[
1481,
63,
91
],
[
91,
24... | [
[
[
"Polymyxin B",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mestranol"
]
],
[
[
"Polymyxin B",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Estradiol"
],
[
... | Polymyxin B may cause a moderate interaction that could exacerbate diseases when taken with Estradiol and Estradiol (Compound) resembles Mestranol (Compound)
Polymyxin B may cause a moderate interaction that could exacerbate diseases when taken with Sulfasalazine and Sulfasalazine may cause a moderate interaction that ... |
DB01261 | DB08881 | 170 | 868 | [
"DDInter1679",
"DDInter1925"
] | Sitagliptin | Vemurafenib | Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256]. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improv... | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Moderate | 1 | [
[
[
170,
24,
868
]
],
[
[
170,
6,
8374
],
[
8374,
45,
868
]
],
[
[
170,
18,
6824
],
[
6824,
46,
868
]
],
[
[
170,
7,
14983
],
[
14983,
... | [
[
[
"Sitagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Sitagliptin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound... | Sitagliptin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound)
Sitagliptin (Compound) downregulates CHAC1 (Gene) and CHAC1 (Gene) is upregulated by Vemurafenib (Compound)
Sitagliptin (Compound) upregulates PIGB (Gene) and PIGB (Gene) is upregulated by Vemurafenib (Compound)
Sitagliptin ... |
DB00762 | DB09073 | 613 | 951 | [
"DDInter973",
"DDInter1379"
] | Irinotecan | Palbociclib | Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cel... | Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties. Palbociclib was developed by Pfizer Inc after the discovery tha... | Moderate | 1 | [
[
[
613,
24,
951
]
],
[
[
613,
62,
1230
],
[
1230,
23,
951
]
],
[
[
613,
24,
496
],
[
496,
63,
951
]
],
[
[
613,
24,
259
],
[
259,
2... | [
[
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palbociclib"
]
],
[
[
"Irinotecan",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Citalopram"
],
[
... | Irinotecan may cause a minor interaction that can limit clinical effects when taken with Citalopram and Citalopram may cause a minor interaction that can limit clinical effects when taken with Palbociclib
Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine and ... |
DB00945 | DB11703 | 1,479 | 405 | [
"DDInter20",
"DDInter9"
] | Acetylsalicylic acid | Acalabrutinib | Also known as _Aspirin_, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial... | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor... | Major | 2 | [
[
[
1479,
25,
405
]
],
[
[
1479,
24,
1384
],
[
1384,
24,
405
]
],
[
[
1479,
63,
383
],
[
383,
24,
405
]
],
[
[
1479,
62,
353
],
[
353,
... | [
[
[
"Acetylsalicylic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Acetylsalicylic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magaldrate"
],
... | Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Magaldrate and Magaldrate may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB04861 | DB08881 | 1,592 | 868 | [
"DDInter1271",
"DDInter1925"
] | Nebivolol | Vemurafenib | Nebivolol is a racemic mixture of 2 enantiomers where one is a beta adrenergic antagonist and the other acts as a cardiac stimulant without beta adrenergic activity. Treatment with nebivolol leads to a greater decrease in systolic and diastolic blood pressure than [atenolol], [propranolol], or [pindolol]. Nebivolol and... | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Moderate | 1 | [
[
[
1592,
24,
868
]
],
[
[
1592,
6,
12523
],
[
12523,
45,
868
]
],
[
[
1592,
21,
28714
],
[
28714,
60,
868
]
],
[
[
1592,
63,
608
],
[
608... | [
[
[
"Nebivolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Nebivolol",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
... | Nebivolol (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Vemurafenib (Compound)
Nebivolol (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Vemurafenib (Compound)
Nebivolol may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocain... |
DB00046 | DB01238 | 1,179 | 673 | [
"DDInter940",
"DDInter118"
] | Insulin lispro | Aripiprazole | Insulin lispro is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promote... | Aripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania. Aripiprazole exerts its effects thr... | Moderate | 1 | [
[
[
1179,
24,
673
]
],
[
[
1179,
24,
1630
],
[
1630,
1,
673
]
],
[
[
1179,
24,
1039
],
[
1039,
24,
673
]
],
[
[
1179,
24,
761
],
[
761,
... | [
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aripiprazole"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Perphenazine"
... | Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Perphenazine and Perphenazine (Compound) resembles Aripiprazole (Compound)
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine and Dexfenfluramine may cause a moderat... |
DB00743 | DB09340 | 808 | 1,013 | [
"DDInter792",
"DDInter1895"
] | Gadobenic acid | Tyropanoic acid | Gadobenic acid, usually available in the salt form gadobenate dimeglumine, is a linear MRI gadolinium-based contrast agent (GBCA) used primarily for MR imaging of the liver. It differs from other GBCAs due to the benzene ring that confers weak protein binding, thus leading to an increased R1 and R2 relaxivity. As gadob... | Tyropanoic acid is a radiocontrast agent used in cholecystography, the X-ray diagnosis of gallstones under the trade names include Bilopaque, Lumopaque, Tyropaque, and Bilopac. The molecule contains three heavy iodine atoms which obstruct X-rays in the same way as the calcium in bones, which results in a visible image ... | Moderate | 1 | [
[
[
808,
24,
1013
]
],
[
[
808,
24,
819
],
[
819,
24,
1013
]
],
[
[
808,
63,
1523
],
[
1523,
24,
1013
]
],
[
[
808,
40,
1431
],
[
1431,
... | [
[
[
"Gadobenic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tyropanoic acid"
]
],
[
[
"Gadobenic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acebutolol"
... | Gadobenic acid may cause a moderate interaction that could exacerbate diseases when taken with Acebutolol and Acebutolol may cause a moderate interaction that could exacerbate diseases when taken with Tyropanoic acid
Gadobenic acid may cause a moderate interaction that could exacerbate diseases when taken with Labetalo... |
DB00834 | DB00877 | 932 | 629 | [
"DDInter1215",
"DDInter1678"
] | Mifepristone | Sirolimus | Mifepristone is a progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercor... | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | Major | 2 | [
[
[
932,
25,
629
]
],
[
[
932,
6,
4973
],
[
4973,
45,
629
]
],
[
[
932,
7,
18110
],
[
18110,
46,
629
]
],
[
[
932,
7,
8733
],
[
8733,
... | [
[
[
"Mifepristone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sirolimus"
]
],
[
[
"Mifepristone",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Siroli... | Mifepristone (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Sirolimus (Compound)
Mifepristone (Compound) upregulates ST6GALNAC2 (Gene) and ST6GALNAC2 (Gene) is upregulated by Sirolimus (Compound)
Mifepristone (Compound) upregulates PHGDH (Gene) and PHGDH (Gene) is downregulated by Sirolimus (Compound)
Mifep... |
DB01242 | DB08816 | 1,237 | 578 | [
"DDInter410",
"DDInter1802"
] | Clomipramine | Ticagrelor | Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or aro... | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Moderate | 1 | [
[
[
1237,
24,
578
]
],
[
[
1237,
6,
4973
],
[
4973,
45,
578
]
],
[
[
1237,
21,
28646
],
[
28646,
60,
578
]
],
[
[
1237,
25,
1011
],
[
1011... | [
[
[
"Clomipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Clomipramine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)... | Clomipramine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Ticagrelor (Compound)
Clomipramine (Compound) causes Unspecified disorder of skin and subcutaneous tissue (Side Effect) and Unspecified disorder of skin and subcutaneous tissue (Side Effect) is caused by Ticagrelor (Compound)
Clomipramine may lead ... |
DB01254 | DB06699 | 1,213 | 774 | [
"DDInter484",
"DDInter493"
] | Dasatinib | Degarelix | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH... | Moderate | 1 | [
[
[
1213,
24,
774
]
],
[
[
1213,
63,
521
],
[
521,
1,
774
]
],
[
[
1213,
21,
29232
],
[
29232,
60,
774
]
],
[
[
1213,
62,
112
],
[
112,
... | [
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Degarelix"
]
],
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Goserelin"
],
[
... | Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin (Compound) resembles Degarelix (Compound)
Dasatinib (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Degarelix (Compound)
Dasatinib may cause a minor interaction that can l... |
DB00059 | DB12839 | 1,560 | 919 | [
"DDInter1404",
"DDInter1411"
] | Pegaspargase | Pegvaliase | Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagi... | Pegvaliase is a recombinant phenylalanine ammonia lyase (PAL) enzyme derived from _Anabaena variabilis_ that converts phenylalanine to ammonia and _trans_-cinnamic acid . Both the U.S. Food and Drug Administration and European Medicines Agency approved pegvaliase-pqpz in May 2018 for the treatment of adult patients wit... | Moderate | 1 | [
[
[
1560,
24,
919
]
],
[
[
1560,
63,
1257
],
[
1257,
24,
919
]
],
[
[
1560,
24,
934
],
[
934,
24,
919
]
],
[
[
1560,
25,
375
],
[
375,
... | [
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pegvaliase"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pegfilgrastim"
],
... | Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Pegfilgrastim and Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Pegvaliase
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Pegloticase... |
DB01362 | DB14761 | 497 | 242 | [
"DDInter960",
"DDInter1578"
] | Iohexol | Remdesivir | Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality. | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19), which is a respiratory disease that is capable of progressing to viral pneumonia and acute respiratory distress syndrome (ARDS); COVID-19 can be fatal. Like other RNA viruses, SARS-CoV-2 depends o... | Moderate | 1 | [
[
[
497,
24,
242
]
],
[
[
497,
64,
1512
],
[
1512,
24,
242
]
],
[
[
497,
25,
129
],
[
129,
24,
242
]
],
[
[
497,
1,
258
],
[
258,
24... | [
[
[
"Iohexol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
]
],
[
[
"Iohexol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Diclofenac"
],
[
"Diclofenac",
... | Iohexol may lead to a major life threatening interaction when taken with Diclofenac and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Iohexol may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may cause a moderate intera... |
DB00321 | DB00792 | 21 | 832 | [
"DDInter78",
"DDInter1878"
] | Amitriptyline | Tripelennamine | Amitriptyline is a tricyclic antidepressant that has been used to treat depression for decades. ELAVIL, a previously approved branded product of amitriptyline, was first approved by the FDA in 1961. Amitriptyline has been investigated in the treatment of pain-related conditions, attributed to its analgesic properties. | A histamine H1 antagonist with low sedative action but frequent gastrointestinal irritation. It is used to treat asthma; HAY fever; urticaria; and rhinitis; and also in veterinary applications. Tripelennamine is administered by various routes, including topically. | Moderate | 1 | [
[
[
21,
35,
832
]
],
[
[
21,
1,
11233
],
[
11233,
1,
832
]
],
[
[
21,
24,
100
],
[
100,
63,
832
]
],
[
[
21,
35,
1264
],
[
1264,
63,... | [
[
[
"Amitriptyline",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
]
],
[
[
"Amitriptyline",
"{u} (Compound) resembles {v} (Compound)",
"Dimetacrine"
],
... | Amitriptyline (Compound) resembles Tripelennamine (Compound) and
Amitriptyline (Compound) resembles Dimetacrine (Compound) and Dimetacrine (Compound) resembles Tripelennamine (Compound)
Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may ... |
DB00682 | DB08934 | 126 | 1,200 | [
"DDInter1951",
"DDInter1695"
] | Warfarin | Sofosbuvir | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Sofosbuvir (tradename Sovaldi) is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 bein... | Moderate | 1 | [
[
[
126,
24,
1200
]
],
[
[
126,
24,
214
],
[
214,
63,
1200
]
],
[
[
126,
24,
913
],
[
913,
64,
1200
]
],
[
[
126,
24,
129
],
[
129,
... | [
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sofosbuvir"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
],
[
... | Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Sofosbuvir
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalu... |
DB00108 | DB06772 | 1,066 | 310 | [
"DDInter1268",
"DDInter259"
] | Natalizumab | Cabazitaxel | Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA re... | Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more ... | Major | 2 | [
[
[
1066,
25,
310
]
],
[
[
1066,
25,
973
],
[
973,
24,
310
]
],
[
[
1066,
25,
800
],
[
800,
63,
310
]
],
[
[
1066,
64,
1451
],
[
1451,
... | [
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Paclitaxel"
],
[
"Paclitaxel",
"{u... | Natalizumab may lead to a major life threatening interaction when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Natalizumab may lead to a major life threatening interaction when taken with Duvelisib and Duvelisib may cause a moderate int... |
DB00445 | DB04865 | 322 | 4 | [
"DDInter655",
"DDInter1335"
] | Epirubicin | Omacetaxine mepesuccinate | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the pla... | Moderate | 1 | [
[
[
322,
24,
4
]
],
[
[
322,
7,
14560
],
[
14560,
46,
4
]
],
[
[
322,
18,
5106
],
[
5106,
46,
4
]
],
[
[
322,
33,
4157
],
[
4157,
46... | [
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Epirubicin",
"{u} (Compound) upregulates {v} (Gene)",
"STAP2"
],
[
"STAP2",
"{u} (Gene) is upregu... | Epirubicin (Compound) upregulates STAP2 (Gene) and STAP2 (Gene) is upregulated by Omacetaxine mepesuccinate (Compound)
Epirubicin (Compound) downregulates ARID4B (Gene) and ARID4B (Gene) is upregulated by Omacetaxine mepesuccinate (Compound)
Epirubicin (Compound) binds CHD1 (Gene) and Epirubicin (Compound) downregulate... |
DB00615 | DB11718 | 690 | 927 | [
"DDInter1589",
"DDInter640"
] | Rifabutin | Encorafenib | A broad-spectrum antibiotic that is being used as prophylaxis against disseminated Mycobacterium avium complex infection in HIV-positive patients. | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Major | 2 | [
[
[
690,
25,
927
]
],
[
[
690,
24,
112
],
[
112,
23,
927
]
],
[
[
690,
1,
1088
],
[
1088,
24,
927
]
],
[
[
690,
24,
1491
],
[
1491,
... | [
[
[
"Rifabutin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
]
],
[
[
"Rifabutin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Metronid... | Rifabutin may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Encorafenib
Rifabutin (Compound) resembles Rifaximin (Compound) and Rifaximin may cause a moderate interaction that coul... |
DB00346 | DB11730 | 472 | 351 | [
"DDInter44",
"DDInter1588"
] | Alfuzosin | Ribociclib | Benign prostatic hyperplasia (BPH) refers to a benign growth or hyperplasia of the prostate and leads to lower urinary tract symptoms in men, such as urgency, frequency and changes to urine flow. The prevalence of BPH is as high as 50%-60% for males in their 60's, and this prevalence increases to 80%-90% of those over ... | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Major | 2 | [
[
[
472,
25,
351
]
],
[
[
472,
23,
112
],
[
112,
23,
351
]
],
[
[
472,
24,
283
],
[
283,
62,
351
]
],
[
[
472,
24,
355
],
[
355,
24,... | [
[
[
"Alfuzosin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
]
],
[
[
"Alfuzosin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazo... | Alfuzosin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Alfuzosin may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedrat... |
DB00008 | DB01030 | 491 | 869 | [
"DDInter1407",
"DDInter1835"
] | Peginterferon alfa-2a | Topotecan | Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most co... | An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I. | Moderate | 1 | [
[
[
491,
24,
869
]
],
[
[
491,
24,
310
],
[
310,
63,
869
]
],
[
[
491,
24,
482
],
[
482,
24,
869
]
],
[
[
491,
25,
1064
],
[
1064,
2... | [
[
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
]
],
[
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazi... | Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Topotecan
Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB00294 | DB12130 | 1,336 | 1,017 | [
"DDInter701",
"DDInter1094"
] | Etonogestrel | Lorlatinib | Etonogestrel molecule is a 3-ketodesogestrel or 19-nortestosterone which is a synthetic biologically active metabolite of progestin desogestrel. The first product including etonogestrel was developed by the Merck subsidiary Organon and FDA approved in 2001. | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Moderate | 1 | [
[
[
1336,
24,
1017
]
],
[
[
1336,
25,
1101
],
[
1101,
23,
1017
]
],
[
[
1336,
24,
590
],
[
590,
24,
1017
]
],
[
[
1336,
23,
14
],
[
14,
... | [
[
[
"Etonogestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Etonogestrel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bexarotene"
],
[
"Bexaro... | Etonogestrel may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Etonogestrel may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide and Acetohexamide ma... |
DB03619 | DB08875 | 557 | 1,618 | [
"DDInter501",
"DDInter262"
] | Deoxycholic acid | Cabozantinib | Deoxycholic acid is a a bile acid which emulsifies and solubilizes dietary fats in the intestine, and when injected subcutaneously, it disrupts cell membranes in adipocytes and destroys fat cells in that tissue. In April 2015, deoxycholic acid was approved by the FDA for the treatment submental fat to improve aesthetic... | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Moderate | 1 | [
[
[
557,
24,
1618
]
],
[
[
557,
24,
1040
],
[
1040,
63,
1618
]
],
[
[
557,
63,
885
],
[
885,
25,
1618
]
],
[
[
557,
24,
503
],
[
503,
... | [
[
[
"Deoxycholic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabozantinib"
]
],
[
[
"Deoxycholic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
... | Deoxycholic acid may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Deoxycholic acid may cause a moderate interaction that could exacerbate diseases when taken with Epopros... |
DB01037 | DB09080 | 1,161 | 144 | [
"DDInter1653",
"DDInter1331"
] | Selegiline | Olodaterol | A selective, irreversible inhibitor of Type B monoamine oxidase. It is used in newly diagnosed patients with Parkinson's disease. It may slow progression of the clinical disease and delay the requirement for levodopa therapy. It also may be given with levodopa upon onset of disability. (From AMA Drug Evaluations Annual... | Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, v... | Moderate | 1 | [
[
[
1161,
24,
144
]
],
[
[
1161,
75,
1445
],
[
1445,
24,
144
]
],
[
[
1161,
24,
31
],
[
31,
24,
144
]
],
[
[
1161,
64,
1048
],
[
1048,
... | [
[
[
"Selegiline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Selegiline",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
... | Selegiline (Compound) resembles Pseudoephedrine (Compound) and Selegiline may lead to a major life threatening interaction when taken with Pseudoephedrine and Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Selegiline may cause a moderate interaction that could... |
DB09073 | DB15093 | 951 | 1,654 | [
"DDInter1379",
"DDInter1698"
] | Palbociclib | Somapacitan | Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties. Palbociclib was developed by Pfizer Inc after the discovery tha... | Somapacitan, also known as NNC0195-0092, is a growth hormone analog indicated to treat adults with growth hormone deficiency.[A219126,L15661] This human growth hormone analog differs by the creation of an albumin binding site, and prolonging the effect so that it requires weekly dosing rather than daily. Somapacitan wa... | Moderate | 1 | [
[
[
951,
24,
1654
]
],
[
[
951,
24,
351
],
[
351,
24,
1654
]
],
[
[
951,
63,
467
],
[
467,
24,
1654
]
],
[
[
951,
25,
676
],
[
676,
... | [
[
[
"Palbociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
]
],
[
[
"Palbociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[... | Palbociclib may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Palbociclib may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Si... |
DB09291 | DB11793 | 741 | 738 | [
"DDInter1615",
"DDInter1297"
] | Rolapitant | Niraparib | Rolapitant is a potent, highly selective, long-acting Neurokinin-1 (NK-1) receptor antagonist approved for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in adults. Delayed-phase CINV typically occurs >24 hours after chemotherapy treatment and is principally mediated by Neurokinin-1 and its l... | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, f... | Moderate | 1 | [
[
[
741,
24,
738
]
],
[
[
741,
24,
1033
],
[
1033,
63,
738
]
],
[
[
741,
63,
663
],
[
663,
24,
738
]
],
[
[
741,
64,
759
],
[
759,
2... | [
[
[
"Rolapitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
]
],
[
[
"Rolapitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
],
[
... | Rolapitant may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib and Alpelisib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Rolapitant may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotr... |
DB05578 | DB14006 | 330 | 972 | [
"DDInter1566",
"DDInter370"
] | Ramucirumab | Choline salicylate | Ramucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stim... | Choline salicylate is an anti-inflammatory pain reliever agent that is related to aspirin. It is used to decrease swelling and to treat mild-moderate pain. It is used to treat arthritis in both children and adults. This medicine can also be used for fever . Choline Salicylate is the choline salt of salicylic acid, used... | Major | 2 | [
[
[
330,
25,
972
]
],
[
[
330,
64,
553
],
[
553,
24,
972
]
],
[
[
330,
63,
1039
],
[
1039,
24,
972
]
],
[
[
330,
25,
1409
],
[
1409,
... | [
[
[
"Ramucirumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Choline salicylate"
]
],
[
[
"Ramucirumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fondaparinux"
],
[
"Fondaparinux"... | Ramucirumab may lead to a major life threatening interaction when taken with Fondaparinux and Fondaparinux may cause a moderate interaction that could exacerbate diseases when taken with Choline salicylate
Ramucirumab may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine and De... |
DB00682 | DB13179 | 126 | 68 | [
"DDInter1951",
"DDInter1882"
] | Warfarin | Troleandomycin | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | A macrolide antibiotic that is similar to erythromycin. | Major | 2 | [
[
[
126,
25,
68
]
],
[
[
126,
24,
319
],
[
319,
23,
68
]
],
[
[
126,
63,
251
],
[
251,
24,
68
]
],
[
[
126,
62,
168
],
[
168,
24,
... | [
[
[
"Warfarin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Troleandomycin"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amoxicillin"
],
[
"Amoxicill... | Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Amoxicillin and Amoxicillin may cause a minor interaction that can limit clinical effects when taken with Troleandomycin
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Bet... |
DB00903 | DB00994 | 1,680 | 361 | [
"DDInter686",
"DDInter1277"
] | Etacrynic acid | Neomycin | A compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. This compound has been classified as ... | Neomycin is a broad-spectrum aminoglycoside antibiotic drug that is derived from the metabolic products of _Streptomyces fradiae_. Neomycin is a complex comprised of three components, neomycin A, B, and C. Neomycin B, also known as [framycetin], is the most active component of the complex and neomycin C is the isomer o... | Major | 2 | [
[
[
1680,
25,
361
]
],
[
[
1680,
63,
1647
],
[
1647,
24,
361
]
],
[
[
1680,
21,
28722
],
[
28722,
60,
361
]
],
[
[
1680,
63,
355
],
[
355,... | [
[
[
"Etacrynic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Neomycin"
]
],
[
[
"Etacrynic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acarbose"
],
[
"Acarbo... | Etacrynic acid may cause a moderate interaction that could exacerbate diseases when taken with Acarbose and Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Neomycin
Etacrynic acid (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Neomycin (Compound)
Et... |
DB00182 | DB01390 | 80 | 1,117 | [
"DDInter84",
"DDInter1683"
] | Amphetamine | Sodium bicarbonate | Amphetamine, a compound discovered over 100 years ago, is one of the more restricted controlled drugs. It was previously used for a large variety of conditions and this changed until this point where its use is highly restricted. Amphetamine, with the chemical formula alpha-methylphenethylamine, was discovered in 1910 ... | Sodium bicarbonate is a white, crystalline powder that is commonly used as a pH buffering agent, an electrolyte replenisher, systemic alkalizer and in topical cleansing solutions. | Moderate | 1 | [
[
[
80,
24,
1117
]
],
[
[
80,
21,
29093
],
[
29093,
60,
1117
]
],
[
[
80,
40,
1529
],
[
1529,
63,
1117
]
],
[
[
80,
40,
939
],
[
939,
... | [
[
[
"Amphetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium bicarbonate"
]
],
[
[
"Amphetamine",
"{u} (Compound) causes {v} (Side Effect)",
"Fatigue"
],
[
"Fatigue",
"{u} (Side Effect) i... | Amphetamine (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Sodium bicarbonate (Compound)
Amphetamine (Compound) resembles Metamfetamine (Compound) and Metamfetamine may cause a moderate interaction that could exacerbate diseases when taken with Sodium bicarbonate
Amphetamine (Compound) r... |
DB00582 | DB00682 | 1,622 | 126 | [
"DDInter1946",
"DDInter1951"
] | Voriconazole | Warfarin | Voriconazole (Vfend, Pfizer) is a triazole antifungal medication used to treat serious fungal infections. It is used to treat invasive fungal infections that are generally seen in patients who are immunocompromised. These include invasive candidiasis, invasive aspergillosis, and emerging fungal infections. The increase... | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Major | 2 | [
[
[
1622,
25,
126
]
],
[
[
1622,
6,
6017
],
[
6017,
45,
126
]
],
[
[
1622,
63,
168
],
[
168,
23,
126
]
],
[
[
1622,
25,
467
],
[
467,
... | [
[
[
"Voriconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Warfarin"
]
],
[
[
"Voriconazole",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Warfa... | Voriconazole (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Warfarin (Compound)
Voriconazole may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Warfarin
Voriconazole may lea... |
DB08868 | DB14811 | 1,011 | 385 | [
"DDInter737",
"DDInter979"
] | Fingolimod | Isatuximab | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially appro... | Isatuximab (formerly SAR650984) is a humanized, IgG1-derived monoclonal antibody (mAb) produced from a Chinese hamster ovary (CHO) cell line.[L12099,A191799] Structurally, isatuximab is comprised of two identical immunoglobulin kappa light chains and two identical immunoglobulin gamma heavy chains. It is a cytolytic an... | Major | 2 | [
[
[
1011,
25,
385
]
],
[
[
1011,
25,
1362
],
[
1362,
24,
385
]
],
[
[
1011,
64,
377
],
[
377,
24,
385
]
],
[
[
1011,
63,
1430
],
[
1430,
... | [
[
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Isatuximab"
]
],
[
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Olaparib"
],
[
"Olaparib",
"{u} may c... | Fingolimod may lead to a major life threatening interaction when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Isatuximab
Fingolimod may lead to a major life threatening interaction when taken with Mitomycin and Mitomycin may cause a moderate interactio... |
DB00208 | DB01050 | 1,018 | 848 | [
"DDInter1804",
"DDInter900"
] | Ticlopidine | Ibuprofen | Ticlopidine is an effective inhibitor of platelet aggregation. It is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation. Ticlopidine is marketed under the brand name Ticlid and is indicated for patients who ca... | Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics. The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin. Ibuprofen was finally p... | Moderate | 1 | [
[
[
1018,
24,
848
]
],
[
[
1018,
6,
3486
],
[
3486,
45,
848
]
],
[
[
1018,
21,
28652
],
[
28652,
60,
848
]
],
[
[
1018,
23,
297
],
[
297,
... | [
[
[
"Ticlopidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
]
],
[
[
"Ticlopidine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound)"... | Ticlopidine (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Ibuprofen (Compound)
Ticlopidine (Compound) causes Colitis (Side Effect) and Colitis (Side Effect) is caused by Ibuprofen (Compound)
Ticlopidine may cause a minor interaction that can limit clinical effects when taken with Clove and Clove may caus... |
DB00738 | DB11718 | 485 | 927 | [
"DDInter1420",
"DDInter640"
] | Pentamidine | Encorafenib | Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects. | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Moderate | 1 | [
[
[
485,
24,
927
]
],
[
[
485,
23,
112
],
[
112,
23,
927
]
],
[
[
485,
24,
720
],
[
720,
24,
927
]
],
[
[
485,
63,
216
],
[
216,
24,... | [
[
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Pentamidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Pentamidine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Encorafenib
Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil and ... |
DB00622 | DB00877 | 1,081 | 629 | [
"DDInter1287",
"DDInter1678"
] | Nicardipine | Sirolimus | A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents. [Pub... | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | Moderate | 1 | [
[
[
1081,
24,
629
]
],
[
[
1081,
6,
4973
],
[
4973,
45,
629
]
],
[
[
1081,
18,
7478
],
[
7478,
46,
629
]
],
[
[
1081,
18,
3616
],
[
3616,
... | [
[
[
"Nicardipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
]
],
[
[
"Nicardipine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Nicardipine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Sirolimus (Compound)
Nicardipine (Compound) downregulates TRAPPC6A (Gene) and TRAPPC6A (Gene) is upregulated by Sirolimus (Compound)
Nicardipine (Compound) downregulates CDC45 (Gene) and CDC45 (Gene) is downregulated by Sirolimus (Compound)
Nicardip... |
DB00436 | DB06410 | 323 | 1,196 | [
"DDInter179",
"DDInter595"
] | Bendroflumethiazide | Doxercalciferol | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. It has been used in the treatment of familial hyperkalemia, hypertension, edema, and urinary tract disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p810) | Doxercalciferol is a synthetic vitamin D2 analog that undergoes metabolic activation in vivo to form 1α,25-dihydroxyvitamin D2 (1α,25-(OH)2D2), a naturally occurring, biologically active form of vitamin D2. Doxercalciferol is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney d... | Moderate | 1 | [
[
[
323,
24,
1196
]
],
[
[
323,
40,
1014
],
[
1014,
24,
1196
]
],
[
[
323,
24,
286
],
[
286,
63,
1196
]
],
[
[
323,
63,
1331
],
[
1331,
... | [
[
[
"Bendroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxercalciferol"
]
],
[
[
"Bendroflumethiazide",
"{u} (Compound) resembles {v} (Compound)",
"Benzthiazide"
],
[
"Benzthiazide",
... | Bendroflumethiazide (Compound) resembles Benzthiazide (Compound) and Benzthiazide may cause a moderate interaction that could exacerbate diseases when taken with Doxercalciferol
Bendroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxid... |
DB08899 | DB14975 | 129 | 988 | [
"DDInter649",
"DDInter1949"
] | Enzalutamide | Voxelotor | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Voxelotor is a novel hemoglobin S polymerization inhibitor for the treatment of sickle cell disease. This is a genetically inherited condition most prevalent in the Middle East, Africa, and certain parts of India. Sickle cell disease can lead to excruciating pain, stroke, infection, and various other complications aris... | Major | 2 | [
[
[
129,
25,
988
]
],
[
[
129,
25,
466
],
[
466,
23,
988
]
],
[
[
129,
64,
629
],
[
629,
24,
988
]
],
[
[
129,
63,
309
],
[
309,
24,... | [
[
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Voxelotor"
]
],
[
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Darolutamide"
],
[
"Darolutamide",
... | Enzalutamide may lead to a major life threatening interaction when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Voxelotor
Enzalutamide may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus may cause a moderate i... |
DB00741 | DB06717 | 167 | 875 | [
"DDInter885",
"DDInter778"
] | Hydrocortisone | Fosaprepitant | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone wa... | Fosaprepitant is an intravenously administered antiemetic drug. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. | Moderate | 1 | [
[
[
167,
24,
875
]
],
[
[
167,
63,
723
],
[
723,
1,
875
]
],
[
[
167,
21,
29180
],
[
29180,
60,
875
]
],
[
[
167,
63,
1101
],
[
1101,
... | [
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosaprepitant"
]
],
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
... | Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant (Compound) resembles Fosaprepitant (Compound)
Hydrocortisone (Compound) causes Abdominal distension (Side Effect) and Abdominal distension (Side Effect) is caused by Fosaprepitant (Compound)
Hydrocor... |
DB04845 | DB12500 | 309 | 283 | [
"DDInter1001",
"DDInter714"
] | Ixabepilone | Fedratinib | Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. ... | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Moderate | 1 | [
[
[
309,
24,
283
]
],
[
[
309,
24,
351
],
[
351,
23,
283
]
],
[
[
309,
63,
122
],
[
122,
23,
283
]
],
[
[
309,
25,
1339
],
[
1339,
6... | [
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[
... | Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Verapamil and Verapam... |
DB06772 | DB13179 | 310 | 68 | [
"DDInter259",
"DDInter1882"
] | Cabazitaxel | Troleandomycin | Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more ... | A macrolide antibiotic that is similar to erythromycin. | Moderate | 1 | [
[
[
310,
24,
68
]
],
[
[
310,
63,
1101
],
[
1101,
23,
68
]
],
[
[
310,
63,
309
],
[
309,
24,
68
]
],
[
[
310,
24,
760
],
[
760,
24,
... | [
[
[
"Cabazitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troleandomycin"
]
],
[
[
"Cabazitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
... | Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Troleandomycin
Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone and I... |
DB00398 | DB01403 | 79 | 9 | [
"DDInter1702",
"DDInter1175"
] | Sorafenib | Methotrimeprazine | Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular ca... | A phenothiazine with pharmacological activity similar to that of both chlorpromazine and promethazine. It has the histamine-antagonist properties of the antihistamines together with central nervous system effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604) | Moderate | 1 | [
[
[
79,
24,
9
]
],
[
[
79,
24,
1178
],
[
1178,
40,
9
]
],
[
[
79,
24,
1164
],
[
1164,
1,
9
]
],
[
[
79,
25,
684
],
[
684,
40,
... | [
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrimeprazine"
]
],
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluoperazine"
]... | Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine and Trifluoperazine (Compound) resembles Methotrimeprazine (Compound)
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Trimipramine and Trimipramine (Compound) resembles Met... |
DB00224 | DB00731 | 215 | 1,144 | [
"DDInter917",
"DDInter1269"
] | Indinavir | Nateglinide | A potent and specific HIV protease inhibitor that appears to have good oral bioavailability. [PubChem] | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that ... | Moderate | 1 | [
[
[
215,
24,
1144
]
],
[
[
215,
63,
168
],
[
168,
24,
1144
]
],
[
[
215,
6,
6799
],
[
6799,
45,
1144
]
],
[
[
215,
21,
28787
],
[
28787,
... | [
[
[
"Indinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
]
],
[
[
"Indinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
... | Indinavir may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide
Indinavir (Compound) binds CYP3A7 (Gene) and CYP3A7 (Gene) is bound by Nateglinide (Compound)
Indinavir (Compoun... |
DB00603 | DB01174 | 303 | 697 | [
"DDInter1137",
"DDInter1442"
] | Medroxyprogesterone acetate | Phenobarbital | Medroxyprogesterone acetate (MPA) is a [progesterone] derivative that is more resistant to metabolism for improved pharmacokinetic properties. MPA can be use to treat secondary amenorrhea, endometrial hyperplasia, abnormal uterine bleeding, osteoporosis, vasomotor symptoms in menopause, vulvar and vaginal atrophy, prev... | A barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. | Moderate | 1 | [
[
[
303,
24,
697
]
],
[
[
303,
24,
759
],
[
759,
1,
697
]
],
[
[
303,
63,
362
],
[
362,
1,
697
]
],
[
[
303,
63,
536
],
[
536,
40,
... | [
[
[
"Medroxyprogesterone acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenobarbital"
]
],
[
[
"Medroxyprogesterone acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}... | Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Primidone and Primidone (Compound) resembles Phenobarbital (Compound)
Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound)... |
DB00694 | DB04946 | 51 | 924 | [
"DDInter485",
"DDInter907"
] | Daunorubicin | Iloperidone | A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. | Iloperidone is an atypical antipsychotic for the treatment of schizophrenia symptoms. Hoechst Marion Roussel Inc. researched the drug until May 1996. In June 1997 they gave the research rights to Titan Pharmaceuticals, who gave the worldwide development, manufacturing, and marketing rights to Novartis in August 1998. O... | Major | 2 | [
[
[
51,
25,
924
]
],
[
[
51,
24,
1664
],
[
1664,
1,
924
]
],
[
[
51,
64,
1425
],
[
1425,
25,
924
]
],
[
[
51,
24,
519
],
[
519,
40,
... | [
[
[
"Daunorubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iloperidone"
]
],
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risperidone"
],
[
"Risp... | Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Risperidone and Risperidone (Compound) resembles Iloperidone (Compound)
Daunorubicin may lead to a major life threatening interaction when taken with Cisapride and Cisapride may lead to a major life threatening interaction when... |
DB00557 | DB01166 | 252 | 477 | [
"DDInter895",
"DDInter379"
] | Hydroxyzine | Cilostazol | Hydroxyzine is a first-generation histamine H<sub>1</sub>-receptor antagonist of the dephenylmethane and piperazine classes that exhibits sedative, anxiolytic, and antiemetic properties.[A1257,A187589] It was first developed in 1955, and has since remained a relatively common treatment for allergic conditions such as p... | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both prim... | Moderate | 1 | [
[
[
252,
24,
477
]
],
[
[
252,
6,
12523
],
[
12523,
45,
477
]
],
[
[
252,
21,
30397
],
[
30397,
60,
477
]
],
[
[
252,
23,
112
],
[
112,
... | [
[
[
"Hydroxyzine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
]
],
[
[
"Hydroxyzine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)... | Hydroxyzine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Cilostazol (Compound)
Hydroxyzine (Compound) causes Drug eruption (Side Effect) and Drug eruption (Side Effect) is caused by Cilostazol (Compound)
Hydroxyzine may cause a minor interaction that can limit clinical effects when taken with Metronidaz... |
DB08864 | DB09330 | 786 | 985 | [
"DDInter1595",
"DDInter1352"
] | Rilpivirine | Osimertinib | Rilpivirine is non-nucleoside reverse transcriptase inhibitor (NNRTI) which is used for the treatment of HIV-1 infections in treatment-naive patients. It is a diarylpyrimidine derivative. The internal conformational flexibility of rilpivirine and the plasticity of it interacting binding site gives it a very high potenc... | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Major | 2 | [
[
[
786,
25,
985
]
],
[
[
786,
62,
112
],
[
112,
23,
985
]
],
[
[
786,
63,
1478
],
[
1478,
24,
985
]
],
[
[
786,
24,
1040
],
[
1040,
... | [
[
[
"Rilpivirine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
]
],
[
[
"Rilpivirine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metron... | Rilpivirine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Rilpivirine may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Iv... |
DB01017 | DB09275 | 1,669 | 813 | [
"DDInter1224",
"DDInter213"
] | Minocycline | Bismuth subcitrate potassium | Minocycline was first described in the literacture in 1966. It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetr... | A bismuth compound used for peptic ulcer and gastro-oesophageal reflux disease (GORD). | Moderate | 1 | [
[
[
1669,
24,
813
]
],
[
[
1669,
40,
1572
],
[
1572,
24,
813
]
],
[
[
1669,
40,
1572
],
[
1572,
40,
1620
],
[
1620,
24,
813
]
],
[
[
1669,... | [
[
[
"Minocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bismuth subcitrate potassium"
]
],
[
[
"Minocycline",
"{u} (Compound) resembles {v} (Compound)",
"Demeclocycline"
],
[
"Demeclocycline",
... | Minocycline (Compound) resembles Demeclocycline (Compound) and Demeclocycline may cause a moderate interaction that could exacerbate diseases when taken with Bismuth subcitrate potassium
Minocycline (Compound) resembles Demeclocycline (Compound) and Demeclocycline (Compound) resembles Tetracycline (Compound) and Tetrac... |
DB00951 | DB06317 | 1,072 | 1,626 | [
"DDInter986",
"DDInter630"
] | Isoniazid | Elotuzumab | Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis. | Elotuzumab is a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Elotuzumab targets SLAMF7, also known as Signaling Lymphocytic Activation Molecule Family... | Moderate | 1 | [
[
[
1072,
24,
1626
]
],
[
[
1072,
24,
973
],
[
973,
24,
1626
]
],
[
[
1072,
63,
597
],
[
597,
24,
1626
]
],
[
[
1072,
24,
310
],
[
310,
... | [
[
[
"Isoniazid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elotuzumab"
]
],
[
[
"Isoniazid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
],
[
... | Isoniazid may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Elotuzumab
Isoniazid may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chl... |
DB09052 | DB09472 | 250 | 1,383 | [
"DDInter220",
"DDInter1693"
] | Blinatumomab | Sodium sulfate | Blinatumomab is a BiTE-class (bi-specific T-cell engager) constructed monoclonal antibody formed by the recombinant fusion of an anti-CD3 single-chain variable fragment (scFV) and an anti-CD19 scFV through a short peptide linker.[A254836,L44311] CD3 is an antigen expressed on the surface of T-cells, while CD19 is mostl... | Sodium Sulfate Anhydrous is the anhydrous, sodium salt form of sulfuric acid. Sodium sulfate anhydrous disassociates in water to provide sodium ions and sulfate ions. Sodium ion is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. Sodium sulfate... | Moderate | 1 | [
[
[
250,
24,
1383
]
],
[
[
250,
24,
1613
],
[
1613,
24,
1383
]
],
[
[
250,
63,
828
],
[
828,
24,
1383
]
],
[
[
250,
64,
593
],
[
593,
... | [
[
[
"Blinatumomab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Blinatumomab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-... | Blinatumomab may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a and Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Blinatumomab may cause a moderate interaction that could exacerbate diseases when ta... |
DB00030 | DB00861 | 1,685 | 914 | [
"DDInter934",
"DDInter551"
] | Insulin human | Diflunisal | Human Insulin, also known as Regular Insulin, is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Human insulin is produced by recombinant DNA technology and is identical to endogenously produced insulin. Typically prescribed for the management of diabetes mel... | Diflunisal, a salicylate derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with pharmacologic actions similar to other prototypical NSAIAs. Diflunisal possesses anti-inflammatory, analgesic and antipyretic activity. Though its mechanism of action has not been clearly established, most of its actions appear ... | Moderate | 1 | [
[
[
1685,
24,
914
]
],
[
[
1685,
24,
417
],
[
417,
23,
914
]
],
[
[
1685,
24,
1019
],
[
1019,
63,
914
]
],
[
[
1685,
24,
251
],
[
251,
... | [
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diflunisal"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sucralfate"
],
... | Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Sucralfate and Sucralfate may cause a minor interaction that can limit clinical effects when taken with Diflunisal
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort and D... |
DB00400 | DB00762 | 353 | 613 | [
"DDInter843",
"DDInter973"
] | Griseofulvin | Irinotecan | An antifungal antibiotic. Griseofulvin may be given by mouth in the treatment of tinea infections. | Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cel... | Moderate | 1 | [
[
[
353,
24,
613
]
],
[
[
353,
6,
8374
],
[
8374,
45,
613
]
],
[
[
353,
21,
28658
],
[
28658,
60,
613
]
],
[
[
353,
24,
536
],
[
536,
... | [
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Irinotecan"
]
],
[
[
"Griseofulvin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compoun... | Griseofulvin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Irinotecan (Compound)
Griseofulvin (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Irinotecan (Compound)
Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Secobarbital an... |
DB00640 | DB13074 | 1,585 | 877 | [
"DDInter31",
"DDInter1110"
] | Adenosine | Macimorelin | The structure of adenosine was first described in 1931, though the vasodilating effects were not described in literature until the 1940s. Adenosine is indicated as an adjunct to thallium-201 in myocardial perfusion scintigraphy, though it is rarely used in this indication, having largely been replaced by [dipyridamole]... | Macimorelin, a novel and orally active ghrelin mimetic that stimulates GH secretion, is used in the diagnosis of adult GH deficiency (AGHD). More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dep... | Moderate | 1 | [
[
[
1585,
24,
877
]
],
[
[
1585,
24,
913
],
[
913,
24,
877
]
],
[
[
1585,
63,
966
],
[
966,
24,
877
]
],
[
[
1585,
24,
485
],
[
485,
... | [
[
[
"Adenosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macimorelin"
]
],
[
[
"Adenosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
],
[
... | Adenosine may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalutamide may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin
Adenosine may cause a moderate interaction that could exacerbate diseases when taken with Octreotide and Octre... |
DB00530 | DB00553 | 1,195 | 92 | [
"DDInter667",
"DDInter1177"
] | Erlotinib | Methoxsalen | Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR)... | A naturally occurring furocoumarin compound found in several species of plants, including Psoralea corylifolia. It is a photoactive substance that forms DNA adducts in the presence of ultraviolet A irradiation. | Moderate | 1 | [
[
[
1195,
24,
92
]
],
[
[
1195,
6,
8374
],
[
8374,
45,
92
]
],
[
[
1195,
7,
2602
],
[
2602,
46,
92
]
],
[
[
1195,
18,
6495
],
[
6495,
... | [
[
[
"Erlotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methoxsalen"
]
],
[
[
"Erlotinib",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Erlotinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Methoxsalen (Compound)
Erlotinib (Compound) upregulates PTK2B (Gene) and PTK2B (Gene) is upregulated by Methoxsalen (Compound)
Erlotinib (Compound) downregulates S100A6 (Gene) and S100A6 (Gene) is downregulated by Methoxsalen (Compound)
Erlotinib (C... |
DB00757 | DB01611 | 1,166 | 1,487 | [
"DDInter581",
"DDInter893"
] | Dolasetron | Hydroxychloroquine | Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. This drug is no... | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxyc... | Major | 2 | [
[
[
1166,
25,
1487
]
],
[
[
1166,
25,
1520
],
[
1520,
25,
1487
]
],
[
[
1166,
6,
12523
],
[
12523,
45,
1487
]
],
[
[
1166,
21,
28803
],
[
... | [
[
[
"Dolasetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Dolasetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Primaquine"
],
[
"Primaquine",
... | Dolasetron may lead to a major life threatening interaction when taken with Primaquine and Primaquine may lead to a major life threatening interaction when taken with Hydroxychloroquine
Dolasetron (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Hydroxychloroquine (Compound)
Dolasetron (Compound) causes Ana... |
DB00959 | DB01124 | 1,486 | 1,411 | [
"DDInter1191",
"DDInter1828"
] | Methylprednisolone | Tolbutamide | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was ... | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release... | Moderate | 1 | [
[
[
1486,
24,
1411
]
],
[
[
1486,
24,
959
],
[
959,
40,
1411
]
],
[
[
1486,
63,
245
],
[
245,
40,
1411
]
],
[
[
1486,
21,
28746
],
[
28746... | [
[
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
]
],
[
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"... | Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Tolbutamide (Compound)
Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Tolbu... |
DB06335 | DB11986 | 761 | 484 | [
"DDInter1646",
"DDInter648"
] | Saxagliptin | Entrectinib | Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009. | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Moderate | 1 | [
[
[
761,
24,
484
]
],
[
[
761,
63,
222
],
[
222,
23,
484
]
],
[
[
761,
63,
1197
],
[
1197,
24,
484
]
],
[
[
761,
24,
1320
],
[
1320,
... | [
[
[
"Saxagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Saxagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
... | Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Norethisterone and... |
DB11363 | DB14761 | 1,276 | 242 | [
"DDInter39",
"DDInter1578"
] | Alectinib | Remdesivir | Alectinib is a second generation oral drug that selectively inhibits the activity of anaplastic lymphoma kinase (ALK) tyrosine kinase. It is specifically used in the treatment of non-small cell lung cancer (NSCLC) expressing the ALK-EML4 (echinoderm microtubule-associated protein-like 4) fusion protein that causes prol... | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19), which is a respiratory disease that is capable of progressing to viral pneumonia and acute respiratory distress syndrome (ARDS); COVID-19 can be fatal. Like other RNA viruses, SARS-CoV-2 depends o... | Moderate | 1 | [
[
[
1276,
24,
242
]
],
[
[
1276,
64,
1377
],
[
1377,
24,
242
]
],
[
[
1276,
63,
384
],
[
384,
24,
242
]
],
[
[
1276,
64,
1377
],
[
1377,
... | [
[
[
"Alectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
]
],
[
[
"Alectinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide... | Alectinib may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Alectinib may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause ... |
DB00377 | DB09330 | 1,494 | 985 | [
"DDInter1382",
"DDInter1352"
] | Palonosetron | Osimertinib | Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first... | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Major | 2 | [
[
[
1494,
25,
985
]
],
[
[
1494,
23,
1247
],
[
1247,
23,
985
]
],
[
[
1494,
24,
480
],
[
480,
24,
985
]
],
[
[
1494,
24,
657
],
[
657,
... | [
[
[
"Palonosetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
]
],
[
[
"Palonosetron",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"S... | Palonosetron may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Formoter... |
DB00514 | DB01100 | 506 | 1,568 | [
"DDInter527",
"DDInter1470"
] | Dextromethorphan | Pimozide | Dextromethorphan is a levorphanol derivative and codeine analog commonly used as a cough suppressant and also a drug of abuse. Although similar in structure to other opioids, it has minimal interaction with opioid receptors. Dextromethorphan was granted FDA approval before 3 December 1957.[A215412,L14997] | A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to haloperidol for the suppression of vocal and motor tics in patients with Tourette syndrome. Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug ... | Moderate | 1 | [
[
[
506,
24,
1568
]
],
[
[
506,
63,
78
],
[
78,
40,
1568
]
],
[
[
506,
6,
7940
],
[
7940,
45,
1568
]
],
[
[
506,
7,
8386
],
[
8386,
... | [
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pimozide"
]
],
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Droperidol"
]... | Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Droperidol and Droperidol (Compound) resembles Pimozide (Compound)
Dextromethorphan (Compound) binds OPRK1 (Gene) and OPRK1 (Gene) is bound by Pimozide (Compound)
Dextromethorphan (Compound) upregulates MTHFD2 (Gene) and MT... |
DB00495 | DB00888 | 139 | 1,001 | [
"DDInter1961",
"DDInter1133"
] | Zidovudine | Mechlorethamine | A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain... | A vesicant and necrotizing irritant destructive to mucous membranes, mechlorethamine is an alkylating drug. It was formerly used as a war gas. The hydrochloride is used as an antineoplastic in Hodgkin's disease and lymphomas. It causes severe gastrointestinal and bone marrow damage. The FDA granted marketing approval f... | Moderate | 1 | [
[
[
139,
24,
1001
]
],
[
[
139,
24,
450
],
[
450,
1,
1001
]
],
[
[
139,
21,
28725
],
[
28725,
60,
1001
]
],
[
[
139,
24,
51
],
[
51,
... | [
[
[
"Zidovudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mechlorethamine"
]
],
[
[
"Zidovudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclophosphamide"
... | Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Cyclophosphamide and Cyclophosphamide (Compound) resembles Mechlorethamine (Compound)
Zidovudine (Compound) causes Pancytopenia (Side Effect) and Pancytopenia (Side Effect) is caused by Mechlorethamine (Compound)
Zidovudine may c... |
DB00241 | DB12141 | 288 | 971 | [
"DDInter257",
"DDInter817"
] | Butalbital | Gilteritinib | Butalbital, or 5-allyl-5-isobutylbarbituric acid, is a derivative of barbituric acid which the hydrogens at position 5 are substituted by an allyl group and an isobutyl group. It is a short-to-intermediate acting member of barbiturates that exhibit muscle-relaxing and anti-anxiety properties that produce central nervou... | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression... | Moderate | 1 | [
[
[
288,
24,
971
]
],
[
[
288,
24,
1135
],
[
1135,
23,
971
]
],
[
[
288,
24,
466
],
[
466,
62,
971
]
],
[
[
288,
40,
1023
],
[
1023,
... | [
[
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
],
[
... | Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolu... |
DB00279 | DB00988 | 1,152 | 817 | [
"DDInter1074",
"DDInter584"
] | Liothyronine | Dopamine | Liothyronine is a thyroidal hormone T3 which is normally produced by the thyroid gland in a ratio 4:1 when compared with T4: T3. Liothyronine is the active form of thyroxine which is composed in a basic chemical structure by a tyrosine with bound iodine. The exogenous liothyronine product was developed by King Pharmace... | One of the catecholamine neurotransmitters in the brain. It is derived from tyrosine and is the precursor to norepinephrine and epinephrine. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (receptors, dopamine) mediate its action. | Moderate | 1 | [
[
[
1152,
24,
817
]
],
[
[
1152,
24,
532
],
[
532,
1,
817
]
],
[
[
1152,
1,
1191
],
[
1191,
1,
817
]
],
[
[
1152,
24,
874
],
[
874,
... | [
[
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dopamine"
]
],
[
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dobutamine"
],
[
... | Liothyronine may cause a moderate interaction that could exacerbate diseases when taken with Dobutamine and Dobutamine (Compound) resembles Dopamine (Compound)
Liothyronine (Compound) resembles Levodopa (Compound) and Levodopa (Compound) resembles Dopamine (Compound)
Liothyronine may cause a moderate interaction that c... |
DB00047 | DB01238 | 176 | 673 | [
"DDInter932",
"DDInter118"
] | Insulin glargine | Aripiprazole | Insulin glargine is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas t... | Aripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania. Aripiprazole exerts its effects thr... | Moderate | 1 | [
[
[
176,
24,
673
]
],
[
[
176,
24,
1630
],
[
1630,
1,
673
]
],
[
[
176,
24,
1039
],
[
1039,
24,
673
]
],
[
[
176,
24,
761
],
[
761,
... | [
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aripiprazole"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Perphenazine"... | Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Perphenazine and Perphenazine (Compound) resembles Aripiprazole (Compound)
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine and Dexfenfluramine may cause a mod... |
DB06081 | DB06605 | 1,046 | 1,409 | [
"DDInter286",
"DDInter108"
] | Caplacizumab | Apixaban | Caplacizumab, firstly called ALX-0081, is a humanized single-variable-domain immunoglobulin consisting of two identical humanized building blocks genetically linked by a three-alanine linker. Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019, and approved previously by the EU i... | Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FD... | Major | 2 | [
[
[
1046,
25,
1409
]
],
[
[
1046,
23,
539
],
[
539,
62,
1409
]
],
[
[
1046,
63,
109
],
[
109,
24,
1409
]
],
[
[
1046,
24,
41
],
[
41,
... | [
[
[
"Caplacizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apixaban"
]
],
[
[
"Caplacizumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capsicum"
],
[
"Capsicum",
... | Caplacizumab may cause a minor interaction that can limit clinical effects when taken with Capsicum and Capsicum may cause a minor interaction that can limit clinical effects when taken with Apixaban
Caplacizumab may cause a moderate interaction that could exacerbate diseases when taken with Duloxetine and Duloxetine m... |
DB00381 | DB05239 | 376 | 866 | [
"DDInter79",
"DDInter425"
] | Amlodipine | Cobimetinib | Amlodipine, initially approved by the FDA in 1987, is a popular antihypertensive drug belonging to the group of drugs called _dihydropyridine calcium channel blockers_. Due to their selectivity for the peripheral blood vessels, dihydropyridine calcium channel blockers are associated with a lower incidence of myocardial... | Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment ... | Moderate | 1 | [
[
[
376,
24,
866
]
],
[
[
376,
24,
214
],
[
214,
63,
866
]
],
[
[
376,
1,
336
],
[
336,
24,
866
]
],
[
[
376,
63,
1101
],
[
1101,
24... | [
[
[
"Amlodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobimetinib"
]
],
[
[
"Amlodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
],
[... | Amlodipine may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Cobimetinib
Amlodipine (Compound) resembles Nifedipine (Compound) and Nifedipine may cause a moderate interaction that ... |
DB06210 | DB08880 | 72 | 1,510 | [
"DDInter631",
"DDInter1771"
] | Eltrombopag | Teriflunomide | Eltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked well enough. ITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelet... | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Major | 2 | [
[
[
72,
25,
1510
]
],
[
[
72,
24,
1193
],
[
1193,
62,
1510
]
],
[
[
72,
24,
1033
],
[
1033,
63,
1510
]
],
[
[
72,
63,
473
],
[
473,
... | [
[
[
"Eltrombopag",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
]
],
[
[
"Eltrombopag",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zinc gluconate"
],
[
"Z... | Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Teriflunomide
Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib ... |
DB00801 | DB01181 | 1,563 | 1,532 | [
"DDInter850",
"DDInter906"
] | Halazepam | Ifosfamide | Halazepam is a _benzodiazepine_ derivative drug exerting anxiolytic, anticonvulsant, sedative, a muscle relaxing effects.[A1212, A178114] It has been shown to be less toxic than chlordiazepoxide or diazepam. This drug is no longer marketed in the United States, and was withdrawn by _Schering_, its manufacturer, in 2009... | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | Moderate | 1 | [
[
[
1563,
24,
1532
]
],
[
[
1563,
63,
1648
],
[
1648,
24,
1532
]
],
[
[
1563,
1,
481
],
[
481,
63,
1532
]
],
[
[
1563,
24,
401
],
[
401,
... | [
[
[
"Halazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
],
[
[
"Halazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
... | Halazepam may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide
Halazepam (Compound) resembles Quazepam (Compound) and Quazepam may cause a moderate interaction that could exa... |
DB00331 | DB04938 | 1,645 | 1,423 | [
"DDInter1164",
"DDInter1353"
] | Metformin | Ospemifene | Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.[L12207,A176173] Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "i... | Ospemifene is a new selective non-hormonal estrogen receptor modulator (SERM) that is used for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause. FDA approved on February 26, 2013. | Moderate | 1 | [
[
[
1645,
24,
1423
]
],
[
[
1645,
24,
485
],
[
485,
40,
1423
]
],
[
[
1645,
21,
28883
],
[
28883,
60,
1423
]
],
[
[
1645,
24,
1142
],
[
11... | [
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ospemifene"
]
],
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentamidine"
],
[
... | Metformin may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pentamidine (Compound) resembles Ospemifene (Compound)
Metformin (Compound) causes Skin disorder (Side Effect) and Skin disorder (Side Effect) is caused by Ospemifene (Compound)
Metformin may cause a moderate inter... |
DB09065 | DB11691 | 760 | 1,499 | [
"DDInter424",
"DDInter1258"
] | Cobicistat | Naldemedine | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Naldemedine is an opioid receptor antagonist [FDA Label]. It is a modified form of to which a side chain has been added to increase molecular weight and polar surface area resulting in restricted transport across the blood brain barrier. Naldemedine was approved in 2017 in both the US and Japan for the treatment of Opi... | Moderate | 1 | [
[
[
760,
24,
1499
]
],
[
[
760,
63,
307
],
[
307,
23,
1499
]
],
[
[
760,
64,
932
],
[
932,
24,
1499
]
],
[
[
760,
63,
723
],
[
723,
... | [
[
[
"Cobicistat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naldemedine"
]
],
[
[
"Cobicistat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Modafinil"
],
[
... | Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Naldemedine
Cobicistat may lead to a major life threatening interaction when taken with Mifepristone and Mifepristone may cause... |
DB00211 | DB00687 | 1,290 | 870 | [
"DDInter1213",
"DDInter747"
] | Midodrine | Fludrocortisone | An ethanolamine derivative that is an adrenergic alpha agonist. It is used as a vasoconstrictor agent in the treatment of hypotension. | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to... | Moderate | 1 | [
[
[
1290,
24,
870
]
],
[
[
1290,
21,
28714
],
[
28714,
60,
870
]
],
[
[
1290,
24,
688
],
[
688,
62,
870
]
],
[
[
1290,
23,
1645
],
[
1645,... | [
[
[
"Midodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
]
],
[
[
"Midodrine",
"{u} (Compound) causes {v} (Side Effect)",
"Asthenia"
],
[
"Asthenia",
"{u} (Side Effect) is cau... | Midodrine (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Fludrocortisone (Compound)
Midodrine may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a minor interaction that can limit clinical effects when taken with Fludroco... |
DB01072 | DB08901 | 915 | 1,468 | [
"DDInter129",
"DDInter1492"
] | Atazanavir | Ponatinib | Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). Atazanavir is distinguished from other PIs in that it can be given once daily (rather than requiring multiple doses p... | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Major | 2 | [
[
[
915,
25,
1468
]
],
[
[
915,
25,
478
],
[
478,
24,
1468
]
],
[
[
915,
6,
4973
],
[
4973,
45,
1468
]
],
[
[
915,
21,
29024
],
[
29024,
... | [
[
[
"Atazanavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ponatinib"
]
],
[
[
"Atazanavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may ... | Atazanavir may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Atazanavir (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Ponatinib (Compound)
Atazanavir (Compound) causes Hypertensi... |
DB00468 | DB00845 | 1,424 | 1,490 | [
"DDInter1557",
"DDInter406"
] | Quinine | Clofazimine | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It... | Clofazimine is a highly lipophilic antimicrobial riminophenazine dye used in combination with other agents, such as [dapsone], for the treatment of leprosy. It was originally described in 1957 and was the prototypical riminophenazine dye - a bright-red dye that, in its clinical use, results in long-lasting discoloratio... | Moderate | 1 | [
[
[
1424,
24,
1490
]
],
[
[
1424,
6,
4973
],
[
4973,
45,
1490
]
],
[
[
1424,
21,
28787
],
[
28787,
60,
1490
]
],
[
[
1424,
23,
112
],
[
11... | [
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofazimine"
]
],
[
[
"Quinine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Quinine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Clofazimine (Compound)
Quinine (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Clofazimine (Compound)
Quinine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidaz... |
DB00622 | DB08912 | 1,081 | 1,040 | [
"DDInter1287",
"DDInter462"
] | Nicardipine | Dabrafenib | A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents. [Pub... | Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib... | Moderate | 1 | [
[
[
1081,
24,
1040
]
],
[
[
1081,
6,
4973
],
[
4973,
45,
1040
]
],
[
[
1081,
18,
7478
],
[
7478,
46,
1040
]
],
[
[
1081,
18,
3616
],
[
361... | [
[
[
"Nicardipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Nicardipine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",... | Nicardipine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Dabrafenib (Compound)
Nicardipine (Compound) downregulates TRAPPC6A (Gene) and TRAPPC6A (Gene) is upregulated by Dabrafenib (Compound)
Nicardipine (Compound) downregulates CDC45 (Gene) and CDC45 (Gene) is downregulated by Dabrafenib (Compound)
Nicar... |
DB00673 | DB05316 | 723 | 749 | [
"DDInter112",
"DDInter1467"
] | Aprepitant | Pimavanserin | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective h... | Pimavanserin is an atypical antipsychotic indicated for the treatment of psychiatric disorders. Although the exact mechanism of action is unknown, it is thought that pimavanserin interacts with the serotonin receptors, particularly the 5-HT<sub>2A</sub> and HT<sub>2C</sub> receptors. Unlike other atypical antipsychotic... | Moderate | 1 | [
[
[
723,
24,
749
]
],
[
[
723,
63,
522
],
[
522,
24,
749
]
],
[
[
723,
24,
392
],
[
392,
24,
749
]
],
[
[
723,
25,
594
],
[
594,
63,... | [
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pimavanserin"
]
],
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zafirlukast"
],
[... | Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Zafirlukast and Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Pimavanserin
Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lap... |
DB00761 | DB00850 | 1,621 | 1,630 | [
"DDInter1497",
"DDInter1432"
] | Potassium chloride | Perphenazine | A white crystal or crystalline powder used as an electrolyte replenisher, in the treatment of hypokalemia, in buffer solutions, and in fertilizers and explosives. The FDA withdrew its approval for the use of all solid oral dosage form drug products containing potassium chloride that supply 100 mg or more of potassium p... | An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine. | Major | 2 | [
[
[
1621,
25,
1630
]
],
[
[
1621,
64,
252
],
[
252,
40,
1630
]
],
[
[
1621,
25,
1178
],
[
1178,
40,
1630
]
],
[
[
1621,
21,
28809
],
[
288... | [
[
[
"Potassium chloride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Perphenazine"
]
],
[
[
"Potassium chloride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxyzine"
],
[
"Hydrox... | Potassium chloride may lead to a major life threatening interaction when taken with Hydroxyzine and Hydroxyzine (Compound) resembles Perphenazine (Compound)
Potassium chloride may lead to a major life threatening interaction when taken with Trifluoperazine and Trifluoperazine (Compound) resembles Perphenazine (Compound... |
DB00270 | DB00443 | 1,428 | 251 | [
"DDInter993",
"DDInter195"
] | Isradipine | Betamethasone | Isradipine belongs to the dihydropyridine (DHP) class of calcium channel blockers (CCBs), the most widely used class of CCBs. It is structurally related to felodipine, nifedipine, and nimodipine and is the most potent calcium-channel blocking agent of the DHP class. Isradipine binds to calcium channels with high affini... | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and neg... | Moderate | 1 | [
[
[
1428,
24,
251
]
],
[
[
1428,
24,
617
],
[
617,
40,
251
]
],
[
[
1428,
24,
870
],
[
870,
1,
251
]
],
[
[
1428,
6,
8374
],
[
8374,
... | [
[
[
"Isradipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betamethasone"
]
],
[
[
"Isradipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Budesonide"
],
[... | Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Budesonide and Budesonide (Compound) resembles Betamethasone (Compound)
Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Betametha... |
DB11978 | DB14840 | 124 | 861 | [
"DDInter822",
"DDInter1601"
] | Glasdegib | Ripretinib | Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionalit... | Ripretinib is a kinase inhibitor used for the treatment of advanced gastrointestinal stromal tumor (GIST) that has not adequately responded to other kinase inhibitors such as [sunitinib] and [imatinib]. Ripretinib, also known as Qinlock, is manufactured by Deciphera Pharmaceuticals and was initially approved by the FDA... | Moderate | 1 | [
[
[
124,
24,
861
]
],
[
[
124,
64,
351
],
[
351,
24,
861
]
],
[
[
124,
63,
353
],
[
353,
24,
861
]
],
[
[
124,
25,
1017
],
[
1017,
2... | [
[
[
"Glasdegib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ripretinib"
]
],
[
[
"Glasdegib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",... | Glasdegib may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Ripretinib
Glasdegib may cause a moderate interaction that could exacerbate diseases when taken with Griseofulvin and Griseofulvin may caus... |
DB00912 | DB08899 | 473 | 129 | [
"DDInter1581",
"DDInter649"
] | Repaglinide | Enzalutamide | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Moderate | 1 | [
[
[
473,
24,
129
]
],
[
[
473,
24,
918
],
[
918,
1,
129
]
],
[
[
473,
6,
8374
],
[
8374,
45,
129
]
],
[
[
473,
21,
28703
],
[
28703,
... | [
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bicalutamide"
],
... | Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide and Bicalutamide (Compound) resembles Enzalutamide (Compound)
Repaglinide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enzalutamide (Compound)
Repaglinide (Compound) causes Pruritus (Side Effect) and... |
DB01618 | DB09076 | 776 | 1,116 | [
"DDInter1239",
"DDInter1899"
] | Molindone | Umeclidinium | An indole derivative effective in schizophrenia and other psychoses and possibly useful in the treatment of the aggressive type of undersocialized conduct disorder. Molindone has much lower affinity for D2 receptors than most antipsychotic agents and has a relatively low affinity for D1 receptors. It has only low to mo... | Umeclidinium is a long-acting muscarinic antagonist (LAMA) used as a maintenance treatment for symptoms of chronic obstructive pulmonary disease (COPD). COPD is a progressive obstructive lung disease characterized by shortness of breath, cough, sputum production, and chronically poor airflow with a forced expiratory vo... | Moderate | 1 | [
[
[
776,
24,
1116
]
],
[
[
776,
24,
849
],
[
849,
24,
1116
]
],
[
[
776,
63,
401
],
[
401,
24,
1116
]
],
[
[
776,
24,
103
],
[
103,
... | [
[
[
"Molindone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Umeclidinium"
]
],
[
[
"Molindone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
],
[
... | Molindone may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Umeclidinium
Molindone may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Prom... |
DB04845 | DB08820 | 309 | 1,478 | [
"DDInter1001",
"DDInter997"
] | Ixabepilone | Ivacaftor | Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. ... | Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and... | Moderate | 1 | [
[
[
309,
24,
1478
]
],
[
[
309,
6,
8374
],
[
8374,
45,
1478
]
],
[
[
309,
21,
29998
],
[
29998,
60,
1478
]
],
[
[
309,
62,
307
],
[
307,
... | [
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
]
],
[
[
"Ixabepilone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)"... | Ixabepilone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ivacaftor (Compound)
Ixabepilone (Compound) causes Hyperaesthesia (Side Effect) and Hyperaesthesia (Side Effect) is caused by Ivacaftor (Compound)
Ixabepilone may cause a minor interaction that can limit clinical effects when taken with Modafinil ... |
DB00852 | DB01276 | 1,445 | 123 | [
"DDInter1545",
"DDInter706"
] | Pseudoephedrine | Exenatide | Pseudoephedrine is structurally related to [ephedrine] but exerts a weaker effect on the sympathetic nervous system.[A188820,A188823] Both drugs naturally occur in in ephedra plant which have a history of use in traditional Eastern medicine and were first researched in the west in 1889. The decongestant effect of pseud... | Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulation... | Moderate | 1 | [
[
[
1445,
24,
123
]
],
[
[
1445,
63,
1252
],
[
1252,
23,
123
]
],
[
[
1445,
24,
939
],
[
939,
24,
123
]
],
[
[
1445,
63,
1685
],
[
1685,
... | [
[
[
"Pseudoephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Pseudoephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digoxin"
],
... | Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin may cause a minor interaction that can limit clinical effects when taken with Exenatide
Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Benzphetamine and Be... |
DB01591 | DB06589 | 667 | 1,250 | [
"DDInter1696",
"DDInter1400"
] | Solifenacin | Pazopanib | Solifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency. It has a long duration of action as it is usually taken once daily. Solifenacin was granted FDA approval on 19 November 2004. | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Moderate | 1 | [
[
[
667,
24,
1250
]
],
[
[
667,
6,
8374
],
[
8374,
45,
1250
]
],
[
[
667,
21,
28658
],
[
28658,
60,
1250
]
],
[
[
667,
62,
112
],
[
112,
... | [
[
[
"Solifenacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
]
],
[
[
"Solifenacin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)"... | Solifenacin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Pazopanib (Compound)
Solifenacin (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Pazopanib (Compound)
Solifenacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metr... |
DB06605 | DB12147 | 1,409 | 241 | [
"DDInter108",
"DDInter661"
] | Apixaban | Erdafitinib | Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FD... | In early April of 2019, the US FDA approved Janssen Pharmaceutical Companies' brand name Balversa (erdafitinib) as the first-ever fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for patients with locally advanced or metastatic urothelial carcinoma, with susceptible FGFR3 or FGFR2 genetic alterations... | Moderate | 1 | [
[
[
1409,
24,
241
]
],
[
[
1409,
24,
1456
],
[
1456,
24,
241
]
],
[
[
1409,
24,
982
],
[
982,
63,
241
]
],
[
[
1409,
25,
578
],
[
578,
... | [
[
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Erdafitinib"
]
],
[
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venetoclax"
],
[
... | Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax and Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib
Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib and Ivosideni... |
DB00169 | DB00562 | 386 | 1,014 | [
"DDInter367",
"DDInter188"
] | Cholecalciferol | Benzthiazide | Vitamin D, in general, is a secosteroid generated in the skin when 7-dehydrocholesterol located there interacts with ultraviolet irradiation - like that commonly found in sunlight. Both the endogenous form of vitamin D (that results from 7-dehydrocholesterol transformation), vitamin D3 (cholecalciferol), and the plant-... | Benzthiazide is used to treat hypertension and edema. Like other thiazides, benzthiazide promotes water loss from the body (diuretics). They inhibit Na+/Cl- reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used... | Moderate | 1 | [
[
[
386,
24,
1014
]
],
[
[
386,
24,
811
],
[
811,
40,
1014
]
],
[
[
386,
24,
674
],
[
674,
1,
1014
]
],
[
[
386,
25,
1196
],
[
1196,
... | [
[
[
"Cholecalciferol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benzthiazide"
]
],
[
[
"Cholecalciferol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metolazone"
... | Cholecalciferol may cause a moderate interaction that could exacerbate diseases when taken with Metolazone and Metolazone (Compound) resembles Benzthiazide (Compound)
Cholecalciferol may cause a moderate interaction that could exacerbate diseases when taken with Trichlormethiazide and Trichlormethiazide (Compound) rese... |
DB00023 | DB08913 | 305 | 1,186 | [
"DDInter127",
"DDInter1561"
] | Asparaginase Escherichia coli | Radium Ra 223 dichloride | Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginas... | Radium Ra 223 Dichloride is a radiopharmaceutical containing the radioisotope radium-223 that emits short range but high linear energy alpha particles. As a cation, radium mimics calicum and binds to hydroxyapatite, which is a bone mineral found in areas of high bone turnover as seen in bone metastases. It was first ap... | Moderate | 1 | [
[
[
305,
24,
1186
]
],
[
[
305,
24,
37
],
[
37,
24,
1186
]
],
[
[
305,
24,
1583
],
[
1583,
63,
1186
]
],
[
[
305,
63,
491
],
[
491,
... | [
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Radium Ra 223 dichloride"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when... | Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Lomustine and Lomustine may cause a moderate interaction that could exacerbate diseases when taken with Radium Ra 223 dichloride
Asparaginase Escherichia coli may cause a moderate interaction that could exacerb... |
DB00252 | DB00470 | 362 | 530 | [
"DDInter1460",
"DDInter601"
] | Phenytoin | Dronabinol | Phenytoin is classified as a hydantoin derivative and despite its narrow therapeutic index, it is one of the most commonly used anticonvulsants.[A33595,A188832,A189219] Since it's introduction about 80 years ago, phenytoin has not only been established as an effective anti-epileptic, but has also been investigated for ... | Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effect... | Moderate | 1 | [
[
[
362,
24,
530
]
],
[
[
362,
24,
1614
],
[
1614,
40,
530
]
],
[
[
362,
6,
6017
],
[
6017,
45,
530
]
],
[
[
362,
21,
29226
],
[
29226,
... | [
[
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronabinol"
]
],
[
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nabilone"
],
[
... | Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Nabilone and Nabilone (Compound) resembles Dronabinol (Compound)
Phenytoin (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Dronabinol (Compound)
Phenytoin (Compound) causes Sinusitis (Side Effect) and Sinusitis (Side ... |
DB00531 | DB00978 | 450 | 739 | [
"DDInter456",
"DDInter1084"
] | Cyclophosphamide | Lomefloxacin | Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause steril... | Lomefloxacin is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis and urinary tract infections (UTIs). Additionally, it has been employed for the prophylaxis of UTIs prior to surgery as well. | Minor | 0 | [
[
[
450,
23,
739
]
],
[
[
450,
23,
945
],
[
945,
40,
739
]
],
[
[
450,
62,
1176
],
[
1176,
1,
739
]
],
[
[
450,
62,
1467
],
[
1467,
... | [
[
[
"Cyclophosphamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lomefloxacin"
]
],
[
[
"Cyclophosphamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sparfloxacin"
... | Cyclophosphamide may cause a minor interaction that can limit clinical effects when taken with Sparfloxacin and Sparfloxacin (Compound) resembles Lomefloxacin (Compound)
Cyclophosphamide may cause a minor interaction that can limit clinical effects when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Lome... |
DB01018 | DB09098 | 1,364 | 98 | [
"DDInter847",
"DDInter1700"
] | Guanfacine | Somatrem | Guanfacine, or BS 100-141,[A189838,A189841] is a selective alpha-A2 adrenergic receptor agonist initially indicated for the treatment of hypertension but is now indicated as an extended release tablet for the treatment of ADHD. Guanfacine was first described in the literature in 1974. Guanfacine was granted FDA approva... | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate . Such discussion revolves around whether patients' natural disp... | Moderate | 1 | [
[
[
1364,
24,
98
]
],
[
[
1364,
24,
159
],
[
159,
63,
98
]
],
[
[
1364,
63,
1573
],
[
1573,
24,
98
]
],
[
[
1364,
25,
609
],
[
609,
... | [
[
[
"Guanfacine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Guanfacine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
... | Guanfacine may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Guanfacine may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Pr... |
DB00491 | DB04946 | 127 | 924 | [
"DDInter1217",
"DDInter907"
] | Miglitol | Iloperidone | Miglitol inhibits the breakdown complex carbohydrates into glucose. It is primarily used in diabetes mellitus type 2 for establishing greater glycemic control by preventing the digestion of carbohydrates (such as disaccharides, oligosaccharides, and polysaccharides) into monosaccharides which can be absorbed by the bod... | Iloperidone is an atypical antipsychotic for the treatment of schizophrenia symptoms. Hoechst Marion Roussel Inc. researched the drug until May 1996. In June 1997 they gave the research rights to Titan Pharmaceuticals, who gave the worldwide development, manufacturing, and marketing rights to Novartis in August 1998. O... | Moderate | 1 | [
[
[
127,
24,
924
]
],
[
[
127,
24,
1664
],
[
1664,
1,
924
]
],
[
[
127,
24,
519
],
[
519,
40,
924
]
],
[
[
127,
21,
28809
],
[
28809,
... | [
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloperidone"
]
],
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risperidone"
],
[
... | Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Risperidone and Risperidone (Compound) resembles Iloperidone (Compound)
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Paliperidone and Paliperidone (Compound) resembles Iloperidone (Compou... |
DB10315 | DB11817 | 1,137 | 1,259 | [
"DDInter1127",
"DDInter165"
] | Measles virus vaccine live attenuated | Baricitinib | Measles virus vaccine live attenuated is a live virus vaccine for simultaneous vaccination against measles, which is a common childhood disease. The vaccine is prepared from the attenuated line of measles virus, derived from Enders' attenuated Edmonston strain and propagated in chick embryo cell culture. | Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated... | Major | 2 | [
[
[
1137,
25,
1259
]
],
[
[
1137,
64,
384
],
[
384,
25,
1259
]
],
[
[
1137,
25,
1619
],
[
1619,
64,
1259
]
],
[
[
1137,
25,
351
],
[
351,
... | [
[
[
"Measles virus vaccine live attenuated",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
]
],
[
[
"Measles virus vaccine live attenuated",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Id... | Measles virus vaccine live attenuated may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Baricitinib
Measles virus vaccine live attenuated may lead to a major life threatening interaction when taken with Rucaparib a... |
DB00196 | DB14723 | 600 | 159 | [
"DDInter743",
"DDInter1026"
] | Fluconazole | Larotrectinib | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby prevent... | Moderate | 1 | [
[
[
600,
24,
159
]
],
[
[
600,
23,
222
],
[
222,
23,
159
]
],
[
[
600,
25,
318
],
[
318,
23,
159
]
],
[
[
600,
25,
1375
],
[
1375,
2... | [
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Fluconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sibutramine"
],
... | Fluconazole may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Fluconazole may lead to a major life threatening interaction when taken with Escitalopram and Escitalopram may... |
DB00641 | DB09122 | 467 | 1,613 | [
"DDInter1675",
"DDInter1409"
] | Simvastatin | Peginterferon beta-1a | Simvastatin, also known as the brand name product Zocor, is a lipid-lowering drug derived synthetically from a fermentation product of _Aspergillus terreus_. It belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid levels by inhibiting the endog... | Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years... | Moderate | 1 | [
[
[
467,
24,
1613
]
],
[
[
467,
24,
671
],
[
671,
24,
1613
]
],
[
[
467,
63,
152
],
[
152,
24,
1613
]
],
[
[
467,
64,
600
],
[
600,
... | [
[
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvastatin"
... | Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Fluvastatin and Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Bosent... |
DB00844 | DB09268 | 314 | 1,662 | [
"DDInter1257",
"DDInter1464"
] | Nalbuphine | Picosulfuric acid | A narcotic used as a pain medication. It appears to be an agonist at kappa opioid receptors and an antagonist or partial agonist at mu opioid receptors. Nalbuphine is the only opioid analgesic that is not a controlled substance in the United States. | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been ... | Moderate | 1 | [
[
[
314,
24,
1662
]
],
[
[
314,
63,
1494
],
[
1494,
24,
1662
]
],
[
[
314,
24,
820
],
[
820,
24,
1662
]
],
[
[
314,
64,
475
],
[
475,
... | [
[
[
"Nalbuphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Nalbuphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palonosetron"
],... | Nalbuphine may cause a moderate interaction that could exacerbate diseases when taken with Palonosetron and Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Nalbuphine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazin... |
DB04835 | DB11901 | 1,655 | 913 | [
"DDInter1125",
"DDInter107"
] | Maraviroc | Apalutamide | Maraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the interaction between HIV and CCR5. It was originally labelled as UK-427857 during development but was assigned the Mara... | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Major | 2 | [
[
[
1655,
25,
913
]
],
[
[
1655,
63,
600
],
[
600,
24,
913
]
],
[
[
1655,
64,
609
],
[
609,
24,
913
]
],
[
[
1655,
24,
1320
],
[
1320,
... | [
[
[
"Maraviroc",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apalutamide"
]
],
[
[
"Maraviroc",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazol... | Maraviroc may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Maraviroc may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin m... |
DB00472 | DB05812 | 758 | 1,374 | [
"DDInter758",
"DDInter8"
] | Fluoxetine | Abiraterone | Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies. | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Moderate | 1 | [
[
[
758,
24,
1374
]
],
[
[
758,
6,
1829
],
[
1829,
45,
1374
]
],
[
[
758,
21,
29113
],
[
29113,
60,
1374
]
],
[
[
758,
23,
112
],
[
112,
... | [
[
[
"Fluoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
]
],
[
[
"Fluoxetine",
"{u} (Compound) binds {v} (Gene)",
"ALB"
],
[
"ALB",
"{u} (Gene) is bound by {v} (Compound)",
... | Fluoxetine (Compound) binds ALB (Gene) and ALB (Gene) is bound by Abiraterone (Compound)
Fluoxetine (Compound) causes Hypokalaemia (Side Effect) and Hypokalaemia (Side Effect) is caused by Abiraterone (Compound)
Fluoxetine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and M... |
DB00180 | DB01110 | 1,351 | 86 | [
"DDInter750",
"DDInter1209"
] | Flunisolide (nasal) | Miconazole | Flunisolide can cause developmental toxicity and female reproductive toxicity according to state or federal government labeling requirements. | Miconazole is a broad-spectrum azole antifungal with some activity against Gram-positive bacteria as well. It is widely used to treat mucosal yeast infections, including both oral and vaginal infections; although intravenous miconazole is no longer available, a wide variety of suppositories, creams, gels, and tablet-ba... | Moderate | 1 | [
[
[
1351,
24,
86
]
],
[
[
1351,
6,
8374
],
[
8374,
45,
86
]
],
[
[
1351,
21,
28787
],
[
28787,
60,
86
]
],
[
[
1351,
24,
1091
],
[
1091,
... | [
[
[
"Flunisolide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Miconazole"
]
],
[
[
"Flunisolide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)... | Flunisolide may cause a moderate interaction that could exacerbate diseases when taken with Miconazole
Flunisolide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Miconazole (Compound)
Flunisolide (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Miconazole (Compound)
Flu... |
DB00850 | DB00855 | 1,630 | 213 | [
"DDInter1432",
"DDInter72"
] | Perphenazine | Aminolevulinic acid | An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine. | A compound produced from succinyl-CoA and glycine as an intermediate in heme synthesis. It is used as a photochemotherapy for actinic keratosis. [PubChem] | Major | 2 | [
[
[
1630,
25,
213
]
],
[
[
1630,
7,
7669
],
[
7669,
46,
213
]
],
[
[
1630,
18,
6168
],
[
6168,
57,
213
]
],
[
[
1630,
21,
28766
],
[
28766... | [
[
[
"Perphenazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aminolevulinic acid"
]
],
[
[
"Perphenazine",
"{u} (Compound) upregulates {v} (Gene)",
"DDIT4"
],
[
"DDIT4",
"{u} (Gene) is upregulated by {v} (Com... | Perphenazine (Compound) upregulates DDIT4 (Gene) and DDIT4 (Gene) is upregulated by Aminolevulinic acid (Compound)
Perphenazine (Compound) downregulates IGFBP3 (Gene) and IGFBP3 (Gene) is downregulated by Aminolevulinic acid (Compound)
Perphenazine (Compound) causes Hypotension (Side Effect) and Hypotension (Side Effec... |
DB00619 | DB06674 | 1,419 | 908 | [
"DDInter909",
"DDInter837"
] | Imatinib | Golimumab | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate t... | Major | 2 | [
[
[
1419,
25,
908
]
],
[
[
1419,
24,
336
],
[
336,
24,
908
]
],
[
[
1419,
25,
697
],
[
697,
24,
908
]
],
[
[
1419,
64,
828
],
[
828,
... | [
[
[
"Imatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Golimumab"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nifedipine"
],
[
"Nifedipine",
... | Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine and Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Golimumab
Imatinib may lead to a major life threatening interaction when taken with Phenobarbital and Phenobarbital may cause... |
DB01200 | DB12500 | 469 | 283 | [
"DDInter243",
"DDInter714"
] | Bromocriptine | Fedratinib | Bromocriptine mesylate is a semisynthetic ergot alkaloid derivative with potent dopaminergic activity. It inhibits prolactin secretion and may be used to treat dysfunctions associated with hyperprolactinemia. Bromocriptine is also indicated for the management of signs and symptoms of Parkinsonian Syndrome, as well as t... | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Moderate | 1 | [
[
[
469,
24,
283
]
],
[
[
469,
24,
351
],
[
351,
23,
283
]
],
[
[
469,
63,
1419
],
[
1419,
24,
283
]
],
[
[
469,
40,
628
],
[
628,
2... | [
[
[
"Bromocriptine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Bromocriptine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
... | Bromocriptine may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Bromocriptine may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imat... |
DB06754 | DB10897 | 707 | 539 | [
"DDInter471",
"DDInter291"
] | Danaparoid | Capsicum | Danaparoid is a low-molecular-weight heparinoid with an average molecular weight of 5500 Daltons consisting of a mixture of glycosaminoglycans. The active constituents are heparan, dermatan and, and they are isolated from the porcine intestinal mucosa [FDA Label]. Danaparoid possesses a potent antithrombic activity tha... | Capsicum (Chili pepper) allergenic extract is used in allergenic testing. | Minor | 0 | [
[
[
707,
23,
539
]
],
[
[
707,
64,
885
],
[
885,
23,
539
]
],
[
[
707,
25,
578
],
[
578,
23,
539
]
],
[
[
707,
25,
1421
],
[
1421,
6... | [
[
[
"Danaparoid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capsicum"
]
],
[
[
"Danaparoid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Epoprostenol"
],
[
"Epoprostenol... | Danaparoid may lead to a major life threatening interaction when taken with Epoprostenol and Epoprostenol may cause a minor interaction that can limit clinical effects when taken with Capsicum
Danaparoid may lead to a major life threatening interaction when taken with Ticagrelor and Ticagrelor may cause a minor interac... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.